Prevention and treatment of deep vein thrombosis in cancer patient;La prevention et le traitement de la thrombose veineuse profonde ont- ils une specificite chez le patient cancereux?

Bulletin du Cancer

Volumn 85, Issue 7, 1998, Pages 618-621

  Voog, Éric ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Anticoagulants; Cancer; Deep vein thrombosis

Indexed keywords

ANTIVITAMIN K; HEPARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; DEEP VEIN THROMBOSIS; HUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; TUMOR THROMBUS; BLOOD; NEOPLASM; PATHOPHYSIOLOGY; THROMBOPHLEBITIS;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; NEOPLASMS; THROMBOPHLEBITIS;

EID: 0032116708     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Scates SM. Diagnosis and treatment of cancer-related thrombosis. Semin Thromb Hemost 1992; 18: 373-9.
2. Ambrus JM, Ambrus CM, Mink IB. Causes of death in cancer patients. J Med 1975; 6: 61-4.
3. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study in one hundred eight patients. Part 1. Coagulation studies. Am J Clin Pathol 1979; 71: 10-6.
4. Rickles FR, Edwards J. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31.
5. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996; 10: 457-84.
6. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996; 10: 499-530.
7. Nashitz JE, Yeshurun D, Eldar S, Levy LM. Diagnosis of cancer-associated vascular disorders. Cancer 1996; 77: 1759-67.
8. Clahsen PC, Van de Velde CJH, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a EORTC breast cancer cooperative group study. J Clin Oncol 1994; 12: 1266-71.
9. Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer with thrombotic and hemorragic complications. J Clin Oncol 1987; 5: 1998-2003.
10. Weinmann EE, Salzman EW. Deep vein thrombosis. N Engl J Med 1994; 331: 1630-41.
11. Leizoroviecz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299-309.
12. Poller L, Kernan MC, Thomson JM. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987; 295: 1309-12.
13. Antiplatelet Trialist'Collaboration. Collaborative overview of randomized rrials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235-43.
14. De Moerloose P, Jude B, Lecompte T, Wautier JL. Utilisation des médicaments antiplaquettaires en pratique médicale courante. Sang Thromb Vaiss 1996; 8: 22-32.
15. Conférence de consensus du 8 mars 1991. Prophylaxie des thromboses veineuses profondes er des embolies pulmonaires postopératoires (chirurgie générale, gynécologique et orthopédique). Encyclopédie médicochirurgicale. Anesthésie réanimation 5-1991: 15-20.
16. Levine M, Hirsh J, Arnold A, Warr D, Falanga A, Samosh M, et al. Double blind randomised trial of very-low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
17. Ravaud Ph, Fourcade A, Durieux P. Prophylaxie des thromboses veineuses postopératoires : recommandation de l'Assistance publique-Hòpitaux de Paris. Sang Thromb Vaiss 1995; 7: 119-29.
18. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke, et al. Low molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-6.
19. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venois thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-77.
20. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes PM, Van Der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
21. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
22. Derlon A, Fiessinger JN. Utilisation des antivitamines K en pratique médicale courante. Sang Thromb Vaiss 1996; 8: 15-21.
23. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1993; 103: 1366.
24. Moore FD, Osteen RT, Karp DD, Stelle G, Wilson RE. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 1981; 16: 405-7.
25. Levine M, Rickles F, Kakkar AK. Thrombosis in cancer patients. ASCO 1997 Educational Book: 279-82.
26. Hull RD, Raskob GE, Pineo GF. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
27. Goldhaber SZ, Burling JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trial of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984; 76: 393-7.
28. Ott P, Eldrup E, Oxholme P, Vestergard JB. Streptokinase therapy in the routine management of deep venous thrombosis in the lower extremities: a retrospective study of phlebographic results and therapeutic complications. Acta Med Scand 1986; 219: 295-300.